Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Horst

Showing results (151-160 of 221) with videos related to

Pageof 23
Sort By:
Annals of Surgical Oncology|September 10, 2022
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) ConsortiumJacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, et al.
Blood Cancer Journal|September 16, 2024
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapySophia Gross, Jana Ihlow, Leonie Busack, et al.
Journal of Ovarian Research|July 31, 2023
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinomaPaul Jank, Jonas Leichsenring, Svenja Kolb, et al.
Neoplasia (New York, N.Y.)|September 13, 2023
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancerInga Hoffmann, Mihnea P Dragomir, Nanna Monjé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian CancerSofya Marchenko, Niklas Goernitz, Wiebke Alina Zoern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)Arndt Stahler, Andreas J Kind, Christine Sers, et al.
Molecular Medicine (Cambridge, Mass.)|April 2, 2022
Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancerTudor Moisoiu, Mihnea P Dragomir, Stefania D Iancu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2023
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor gradingSimon Schallenberg, Gabriel Dernbach, Mihnea P Dragomir, et al.
Oncogene|September 26, 2020
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancerMichael Rose, Angela Maurer, Julia Wirtz, et al.
Pageof 23

Showing results (151-160 of 221) with videos related to

Sort By:
Pageof 23
Annals of Surgical Oncology|September 10, 2022
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) ConsortiumJacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, et al.
Blood Cancer Journal|September 16, 2024
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapySophia Gross, Jana Ihlow, Leonie Busack, et al.
Journal of Ovarian Research|July 31, 2023
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinomaPaul Jank, Jonas Leichsenring, Svenja Kolb, et al.
Neoplasia (New York, N.Y.)|September 13, 2023
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancerInga Hoffmann, Mihnea P Dragomir, Nanna Monjé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian CancerSofya Marchenko, Niklas Goernitz, Wiebke Alina Zoern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)Arndt Stahler, Andreas J Kind, Christine Sers, et al.
Molecular Medicine (Cambridge, Mass.)|April 2, 2022
Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancerTudor Moisoiu, Mihnea P Dragomir, Stefania D Iancu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2023
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor gradingSimon Schallenberg, Gabriel Dernbach, Mihnea P Dragomir, et al.
Oncogene|September 26, 2020
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancerMichael Rose, Angela Maurer, Julia Wirtz, et al.
Pageof 23